Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Baxter
Colorcon
Johnson and Johnson
Express Scripts

Last Updated: February 28, 2020

DrugPatentWatch Database Preview

Litigation Details for Auxilium Pharmaceuticals Inc. v. Upsher-Smith Laboratories Inc. (D. Del. 2013)


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Auxilium Pharmaceuticals Inc. v. Upsher-Smith Laboratories Inc. (D. Del. 2013)

Docket   Start Trial Date Filed 2013-01-28
Court District Court, D. Delaware Date Terminated 2013-12-30
Cause 28:1338 Patent Infringement Assigned To Sue Lewis Robinson
Jury Demand None Referred To
Parties AUXILIUM PHARMACEUTICALS INC.; FCB I LLC; UPSHER-SMITH LABORATORIES INC.
Patents 5,023,252; 6,010,718; 6,319,913; 7,214,381; 7,320,968; 7,608,605; 7,608,606; 7,608,607; 7,608,608; 7,608,609; 7,608,610; 7,935,690; 8,063,029; 8,178,518
Attorneys Andrew Colin Mayo; Anne Shea Gaza; Lauren E. Maguire; Steven J. Balick; Travis Steven Hunter
Link to Docket External link to docket
Small Molecule Drugs cited in Auxilium Pharmaceuticals Inc. v. Upsher-Smith Laboratories Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial , and   Start Trial .
Biologic Drugs cited in Auxilium Pharmaceuticals Inc. v. Upsher-Smith Laboratories Inc.
The biologic drug covered by the patents cited in this case is   Start Trial .

Details for Auxilium Pharmaceuticals Inc. v. Upsher-Smith Laboratories Inc. (D. Del. 2013)

Date Filed Document No. Description Snippet Link To Document
2013-01-28 1 infringement of U.S. Patent Nos. 7,320,968 (the “’968 Patent”); 7,608,605 (the “’605 Patent”); 7,608,606 (the…’968 Patent; the ’605 Patent; the ’606 Patent; the ’607 Patent; the ’608 Patent; the ’609 Patent; the…’968 Patent, the ’605 Patent, the ’606 Patent, the ’607 Patent, the ’608 Patent, the ’609 Patent, the…the ’610 Patent; the ’690 Patent; the ’029 Patent; and the ’518 Patent in the Orange Book—formally known…the ’610 Patent, the ’690 Patent, the ’029 Patent, and the ’518 Patent. COUNT I External link to document
2013-12-04 120 Hsieh (U.S. Patent No. 5,023,252 -hereafter "the Hsieh patent"). …enhancer of the type described in U.S. Pat. No. 5,023,252 to Hsieh" ("Hsieh enhancer"). The…type described in U.S. Pat. No. 5,023,252 to Hsieh (assigned to the same assignee as that…the '518 patent, '605 patent, '606 patent, '607 patent, and '609 patent are similarly…'518 patent, 24:14-15; '605 patent, 23:12; '606 patent, 23:39; '607 patent, 23:39, 24 External link to document
2013-12-30 125 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,320,968 B2; 7,608,605 B2; 7,608,606… 30 December 2013 1:13-cv-00148-SLR Patent None District Court, D. Delaware External link to document
2013-01-28 4 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,320,968 B2; 7,608,605 B2; 7,608,606… 30 December 2013 1:13-cv-00148-SLR Patent None District Court, D. Delaware External link to document
2013-05-10 52 tenth patent, all listed in the Orange Book for TESTIM. The first, U.S. Patent No. 7,320,968 (the ’968…apply to two of the patents-in- suit, the ’608 Patent and the ’610 Patent. These patents are continuations…“’606 Patent”); 7,608,607 ( “’607 Patent”); 7,608,608 ( “’608 Patent”); 7,608,609 ( “’609 Patent”); 7,…610 Patent”); 7,935,690 ( “’690 Patent”); 8,063,029 (“’029 Patent”); and 8,178,518 ( “’518 Patent”). (…invention claimed in a 2003 patent, U.S. Patent No 6,503,894, the “Dudley patent.” (Taavola Decl. Ex. 41 External link to document
2013-05-24 66 disclosure and the teachings of the Hsieh patent (U.S. Patent `No. 5,023,252), Gyuril< has only been ailowcd…Dudley et al. (U.S. Patent No` 6,503,894) in view of Hsieh (U.S. Patent No. 5,023,252).” D.l. 58-11 at CPBX0115373…of the ’968 patent, ’605-’607 patent, ’609 patent, ’690 patent029 patent, and ’513 patent Augusrine Mea….S. Patent No. 5,968,919 (on which Gyurik is a named inventor) and the Dudley patent (U.S. Patent No, … reference, citations are to the ’968 patent (the parent patent) specification which is substantialiy External link to document
2013-07-03 75 thereof.” Id. at 1208 (quoting U.S. Pat. No. 6,010,718, at 3:65–67, {00765827;v1 } …foreseeable. 356 F.3d 1357, 1360 (Fed. Cir. 2004). The patent-in-suit claimed a sustained release formulation…class of compounds. In that case, the relevant patent claimed extended release formulations comprising… prove at trial that USL infringes Plaintiffs’ patents under the doctrine of equivalents. There are also…court’s grant of a preliminary injunction where the patent claimed either a mono- or disaccharide and the External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Moodys
McKinsey
Medtronic
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.